• In May 2026, Novanta Inc. reported first-quarter sales of US$257.71 million with essentially flat net income year over year, issued second-quarter and full-year 2026 revenue guidance of US$259 million to US$264 million and US$1.04 billion to US$1.06 billion respectively, and reiterated acquisitions and manufacturing optimization as core priorities.
• Management also highlighted record bookings, strong momentum in Robotics & Automation and Advanced Surgery, and a disciplined acquisition pipeline aimed at enhancing growth while reducing cyclicality and trade sensitivity.
• Now we will consider how this focus on acquisitions and record bookings may reshape Novanta’s existing investment narrative and risk profile.

AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Novanta Investment Narrative Recap

To own Novanta, you need to believe its exposure to robotics, automation and advanced surgery can translate record bookings into sustained earnings growth, while acquisitions supplement slower organic trends. The latest results, with higher sales but essentially flat net income and unchanged focus on M&A, do not materially change the near term catalyst of converting the order book into profitable revenue or the key risk around acquisition execution and manufacturing regionalization.

The most relevant update is management’s reaffirmed priority on acquisitions, backed by a strong pipeline and a sizeable credit facility. This matters because much of Novanta’s near term growth plan still leans on deals to offset weak spots in Precision Medicine and Precision Manufacturing and to reduce trade exposure, so the pace and quality of completed transactions could heavily influence how quickly bookings momentum shows up in reported earnings.

Yet even with record bookings and an active acquisition pipeline, investors should be aware that...

Novanta's narrative projects $1.2 billion revenue and $148.8 million earnings by 2029.

Uncover how Novanta's forecasts yield a $157.00 fair value, in line with its current price.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community span roughly US$105 to US$172 per share, underlining how far apart individual views can be. Before you decide where you stand, consider that much of Novanta’s medium term growth plan still relies on successful acquisitions to supplement modest organic trends and to offset trade and manufacturing risks.

Explore 3 other fair value estimates on Novanta - why the stock might be worth as much as 12% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Novanta research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free Novanta research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Novanta's overall financial health at a glance.

Interested In Other Possibilities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Uncover the next big thing with 27 elite penny stocks that balance risk and reward.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.